2021.May.05

OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: Assessment of the primary endpoint of safety and secondary endpoints of immune response and tumor response […]

HOMEWhat’s NewAnnouncementsOBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2021.Apr.29

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company's Board of Directors resolved to convene the 2021 Annual General Shareholders' Meeting

2021.May.06

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study